BioXcelLogo.png
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
February 04, 2021 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
BioXcelLogo.png
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
January 05, 2021 07:00 ET | BioXcel Therapeutics
Statistically significant, clinically meaningful, rapid and durable reductions in agitation achieved with the 60 mcg dose as measured by multiple agitation scales BXCL501 was well tolerated with no...
BioXcelLogo.png
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 17, 2020 07:00 ET | BioXcel Therapeutics
Company to present corporate update and plans for 2021 Topline TRANQUILITY data expected to be reported by mid-January NEW HAVEN, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,...
BioXcelLogo.png
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
December 07, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcelLogo.png
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 13, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcelLogo.png
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 12, 2020 07:00 ET | BioXcel Therapeutics
Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021 TRANQUILITY and RELEASE studies are on track;...
BioXcelLogo.png
BioXcel Therapeutics Announces Completion of Pre-NDA Meeting with FDA for BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorders
November 11, 2020 07:00 ET | BioXcel Therapeutics
Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”) On track to submit complete NDA in Q1 2021 NEW HAVEN, Conn., Nov. 11, 2020 (GLOBE...
BioXcelLogo.png
BioXcel Therapeutics to Present BXCL701 Clinical Data at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting
November 09, 2020 08:05 ET | BioXcel Therapeutics
Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®) NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel...
BioXcelLogo.png
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast
November 05, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...
BioXcelLogo.png
BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with Delirium
October 26, 2020 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to...